May 5, 2025

Using Bacteria as Living Test Tubes Reveals Human Gene Mutations for New Treatments

Engineered bacteria help rapidly study human gene mutations and identify potential drug treatments, which Moores Member Bernhard Palsson, PhD asserts could accelerate and simplify genetic disease research. Learn More>>

Clinical Trials Day

On May 20, 2025, Moores will celebrate its clinical partners, whose dedication drives discovery, advances science, and transforms lives. Join the celebration to connect with colleagues, community members, and consortium partners and hear from patients whose lives have been changed by your work. Learn More and Register>>

Moores Member Advances Musculoskeletal Health

Researchers in the UC San Diego Muscle Physiology Laboratory, led by Moores Member and Professor of Orthopedic Surgery and Bioengineering, Samuel R. Ward, PhD, are advancing musculoskeletal health by developing noninvasive imaging tools and regenerative therapies to enhance diagnosis, treatment, and rehabilitation. Learn More>>

EDUCATION

Salk Institute Scientific Meetings

Join scientists at the Salk Institute for two events, the Cell Cycle Meeting (July 10–12, 2025) and Mechanisms and Models of Cancer (August 13–15, 2025), each showcasing cutting-edge discoveries in cell biology and cancer research, to connect, collaborate, and explore the future of biomedical science.

FEATURED FUNDING OPPORTUNITIES

Department of Defense (DoD), Congressionally Directed Medical Research Programs (CDMRP), Breast Cancer Research Program (BCRP)

The DoD, CDMRP, BCRP has announced the following research funding opportunities:

Breakthrough Award Level 1 and Level 2

Breakthrough Award Level 3

Clinical Research Extension Award

Era of Hope Scholar Award

DoD, CDMRP, Ovarian Cancer Research Program (OCRP)

The DoD, CDMRP, OCRP has announced the following research funding opportunities:

Investigator-Initiated Research Award

Ovarian Cancer Academy, Early-Career Investigator Award

Pilot Award

RECENT PUBLICATIONS

Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease

Journal of Hepatology

Christopher K. Glass, MD, PhD (Cancer Biology and Signaling [CBS]), Bing Ren, PhD (Structural and Functional Genomics), and Tatiana Kisseleva, MD, PhD (CBS)

Cytoscape web: Bringing network biology to the browser

Nucleic Acids Research

Trey Ideker, PhD (Structural and Functional Genomics)

Transcription-coupled template reconfiguration of 8-oxoguanine for error-prone transcription revealed by time-resolved X-ray crystallography and molecular Dynamics

Journal of the American Chemical Society

Dong Wang, PhD (Cancer Biology and Signaling)

CLINICAL TRIALS OFFICE (CTO)

KT-US-679-0788: A Phase III, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma

PI: Caitlin Costello, MD

NCT ID: NCT06413498

I3Y-MC-JPEH: A Randomized, Open-Label, Phase II Study Evaluating Abemaciclib in Combination with Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults with Newly Diagnosed High-Grade Glioma Following Radiotherapy

PI: Jessica Schulte, MD, PhD

NCT ID: NCT06413706

A022106: Phase II/III Second-Line NABPLAGEM Versus Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

PI: Gregory Botta, MD, PhD

NCT ID: NCT06115499

10528: A Phase I Study of the Polymerase Theta Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors

PI: Shumei Kato, MD

NCT ID: NCT05687110

M23-721: A Randomized, Phase II/III Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

PI: Lyudmila Bazhenova, MD

NCT ID: NCT06236438